Article By:
ChinaBio® Today
Saturday, February 3, 2024 2:40 PM EDT
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.